STL Index for: Brodsky Merrick
Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature
Secukinumab demonstrates rapid and robust clinical improvement accompanied by a favorable short- term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis and psoriatic arthritis treatment.